1550 LINDEN DR
MADISON, WI 53706-1521
Dr. Striker is interested in new approaches to control RNA viruses, particularly Hepatitis C Virus (HCV) and Dengue Virus. His research team has multiple bench top and clinical research projects going on currently, and the unifying theme of these projects is to more fully capitalize on viral genetics to understand and ultimately eradicate specific viral pathogens. The team analyzes clinical databases, and performs wet lab experiments to link functional data with viral genotype. For example, current clinical genotyping methods for HCV convey only a small amount of the useful information that can theoretically be applied to treatment decisions. They recently identified a novel recombinant genotype 2/1 HCV and critical viral polymorphisms associated with response to cyclophilin inhibitors and outcome in liver transplant patients. Studies in flaviviruses are giving new insights into mosquito versus tick transmission.
Search for Robert Striker's literature abstracts on PubMed